Italy - Tosoh Bioscience - Diagnostics EMEA today launched the AIA-CL300, its new compact automated chemiluminescent enzyme immunoassay analyzer. This “small giant” - as it is promoted - is the perfect instrument for small to large laboratories to perform routine analysis, cover emergency use, run specific pathologies and esoteric tests and enhance assay analytical specifications. The AIA-CL300 benefits from the sensitivity, and analytical performances of the AIA-CL technology range with improved ease of use.
Easy to use
The new AIA-CL300 desktop device can run as well in small laboratories as the large ones thanks to its compact size (660 mm height, 640 mm depth and 520 mm width). In terms of usability, its digital touch screen in full colour allows a better visibility to check the inventory of substrate, washer, and diluent which are easily accessible in front compartments of the instrument. The intuitive “One - Touch” Assay Start - a detector standardization cup (STD cup) – eases the daily check process. All these features facilitate the use for the operators and avoid human errors.
Reliability
The AIA-CL300, depending on the assay, can deliver results between 15 minutes (for most analytes) to 35 minutes with a max throughput of 30 tests/hour. Its integrated quality control program with an error-free program automatically checks if reagent cup corresponds to test required. Its advanced technology and automation processes - auto sample dilution, auto pretreatment, auto adjuster reconstitution - prevent human error, reduce manual operation and improve laboratory and diagnostic efficiency leading to better patient outcomes and treatments.
Analytical performance
The AIA-CL300 is a continuous random access automated immunoassay analyser that offers high productivity, excellent analytical sensitivity and precision, and advanced automation features. One unique feature that characterizes the AIA-CL systems is the 1 cup = 1 test concept. This means that all the specific reagents, required to perform one test, are contained inside one cup in a lyophilised form, offering predictable consumption, 90-days calibration stability for all assays, a good traceability of all samples and data. “AIA-CL300 is designed to produce high quality results 24/7. Its advanced technology and automation processes, improve workflows and turnaround time, reduce hands-on-time, prevent operator introduced variability and improve laboratory and diagnostic efficiency leading to better patient outcomes and treatments” emphasized Dr Dimitrios Giantzoudis, Senior Product Manager, Tosoh Bioscience – Diagnostics EMEA.
Contact
Dr. Dimitrios Giantzoudis
Senior Product Manager IVD
Email: [email protected]
Phone: +44 7706 310477
TOSOH CORPORATION
Tosoh Corporation is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 14,000 employes. It generated net sales of ¥1,064,376 billion consolidated financial results for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023).
TOSOH BIOSCIENCE
By bringing the best in quality products, services and technologies from Tosoh Corporation, Tosoh Bioscience. is dedicated to pioneering systems used to assist in monitoring life-threatening diseases and certain cancers, helping to prevent epidemics, purify water, monitor our environment, and making living better for everyone, everywhere.
Tosoh Bioscience is divided in two business units; Tosoh Bioscience - Separation and Tosoh Bioscience - Diagnostics;
Tosoh Bioscience - Separation and purification business unit offer 500+ specialty products in: analytical HPLC columns, chromatographic resins, and GPC instruments to meet laboratory and pharmaceutical needs.
Tosoh Bioscience - Diagnostics Clinical business unit offers superior automated immunoassay and glycohemoglobin analyzers, laboratory solutions, assays and test-cup reagents as solutions to laboratories, clinics, hospitals and veterinarians' needs.